H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Fennec Pharmaceuticals to $17 from $18 and keeps a Buy rating on the shares post the Q2 results. The company’s sales trajectory is proceeding somewhat slower than forecast, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FENC:
- Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update
- Fennec appoints Adrian Haigh as COO
- Fennec reports Q2 EPS (21c), consensus (16c)
- Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023
- Fennec management to meet with Craig-Hallum